Condition: Gram Negative Infection · Antimicrobial Resistance (AMR) · Sponsor: University of Bologna
A multicenter, national, prospective, observational pharmacological study of patients with difficult-to-treat Gram-negative infections treated with ceftazidime/avibactam (CAZ/AVI) or cefiderocol (CEF) monotherapy or combination therapy with ceftazidime/avibactam associated with fosfomycin (FOS) or cefiderocol associated with fosfomycin.
This description comes directly from the study's public registry record.
Maddalena Giannella, MD PhD · +39 0512143199 · maddalena.giannella@unibo.it
Natascia Caroccia, PhD · +39 0512143595 · natascia.caroccia@unibo.it
Always discuss trial participation with your own doctor first.
| Irccs Aoubo | Bologna, Italy | Recruiting |
| Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione (ARNAS) Garibaldi | Catania, Italy | Not Yet Recruiting |
| ASST-FBF-Sacco | Milan, Italy | Not Yet Recruiting |
| Azienda Ospedale - Università Padova | Padova, Italy | Not Yet Recruiting |
| Istituto mediterraneo per i trapianti e terapie ad alta specializzazione (ISMETT) | Palermo, Italy | Not Yet Recruiting |
| Policlinico Umberto I | Rome, Italy | Not Yet Recruiting |
| Policlinico Universitario Campus Bio-Medico | Rome, Italy | Not Yet Recruiting |
| Ospedale Pediatrico Bambin Gesù | Rome, Italy | Not Yet Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Rome, Italy | Not Yet Recruiting |
| Azienda Ospedaliero Universitaria Senese | Siena, Italy | Not Yet Recruiting |
| Città della salute e della Scienza, Molinette | Turin, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06651047